Latest Sanofi Press Releases and News | Sanofi
WEBSep 10, 2024 · Stay informed with the latest Sanofi press releases and news updates. Discover new developments in healthcare and pharmaceuticals with Sanofi.
Sanofi wins US approval for multiple myeloma drug in newly …
WEB2 days ago · Sept 20 - The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's (SASY.PA) Sarclisa infusion as a treatment for certain types of ...
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
WEB2 days ago · FRANKFURT, Sept 20 (Reuters) - Sanofi (SASY.PA) said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French ...
Sanofi pushes ahead with €20bn consumer healthcare spin-off
WEBJun 2, 2024 · The move makes Sanofi the latest Big Pharma company to seek to separate low-margin, consumer businesses from divisions focused on innovative new medicines that offer higher returns.
Sanofi Enters Next Chapter of Play to Win Strategy | Sanofi
WEBOct 27, 2005 · Sanofi today provided a comprehensive update regarding its Play to Win strategy. This strategy continues to focus on the critical goals of executing transformative medicine and vaccines launches, driving agile and efficient resource deployment and enhancing R&D productivity.
Sanofi Pipeline Transformation to Accelerate Growth Driven by …
WEBDec 7, 2002 · Sanofi’s R&D will lead to a 50% increase in the number of Phase 3 studies between 2023 and 2025, creating the greatest pipeline momentum in Sanofi’s history. The company’s commitment to R&D will also support an expected 25 mid- to late-stage read-outs and up to 19 regulatory submissions for its pharma assets in the next two years.
Press Room - Sanofi US News
WEBApr 26, 2024 · Sanofi US News. New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases.
Press Room - Sanofi US News
WEBJul 17, 2023 · Under the terms of the global agreement, Sanofi made an upfront payment of €120m, has paid development and regulatory milestones of €55m and will pay up to a further €440m upon achievement of certain regulatory and sales-related milestones.
Sanofi wins US approval for multiple myeloma drug in newly …
WEB3 days ago · -The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's Sarclisa infusion as a treatment for certain types of newly diagnosed multiple myeloma patients. Sarclisa has previously been approved for use as a fallback therapy for certain cases of multiple myeloma after standard treatments have failed. The French drugmaker, a market ...
Sanofi eyes approval after MS therapy slows disease progression …
WEB2 days ago · Sanofi is eyeing global regulatory approval for tolebrutinib after releasing positive Phase III data in non-relapsing secondary progressive multiple sclerosis (MS),. The results from the HERCULES Phase III trial (NCT04411641) showed that Bruton tyrosine kinase (BTK) inhibitor delayed the time to six-month disability progression by 31% compared to placebo.